Methods For The Effective Treatment Of Metastatic Cancer
AssigneeGeneral Oncology, Inc.
InventorArnold Glazier
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the treatment of metastatic cancer. Methods of treating metastatic cancer by administration of a set of drugs overcome multiple mechanisms of melphalan resistance and hypersensitize cancer cells to melphalan are described. The methods involve the administration of drug(s) that induce oxidative stress in cancer cells, in conjunction with melphalan on a defined schedule.
Claims11
A method of treating metastatic cancer or refractory metastatic cancer in a subject, comprising administering to a subject in need thereof a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea, a redox cycling agent and melphalan or pharmaceutically acceptable salt of any of the foregoing, simultaneously or within a six hour time period;
- wherein the melphalan is at a dose of 20 mg/m2to 200 mg/m2, and then administering an infusion of hematopoietic stem cells.
A method for treatment of metastatic cancer or refractory metastatic cancer in a subject, comprising administering an effective dose of a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea, a redox cycling agent and melphalan, and then administering an infusion of hematopoietic stem cells.
A method for determining treatment response in a subject with refractory metastatic cancer, comprising administering to a subject in need thereof an effective amount of a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea, a redox cycling agent and melphalan or pharmaceutically acceptable salt of any of the foregoing, simultaneously or within a six hour time period;
- wherein the melphalan is at a dose of 20 mg/m2 to 200 mg/m2, then administering an infusion of hematopoietic stem cells;
- and detecting presence of cancer cells in the subject wherein disappearance of detectable cancer cells in the subject is indicative of treatment response.
-32. (canceled)
(canceled)
A set of pharmaceutical agents for use in treating metastatic cancer comprising a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea, a redox cycling agent and melphalan or pharmaceutically acceptable salt of any of the foregoing, wherein the agents are present in a therapeutically effective dose for simultaneous administration or administration within a six hour time period;
- wherein the melphalan is at a dose of 20 mg/m2 to 200 mg/m2.
-39. (canceled)
Dependencies are inferred from the claim text.